NGM Biopharmaceuticals, Inc. (NGM) Tops Q4 EPS by 7c

NGM Biopharmaceuticals, Inc. (NASDAQ: NGM) reported Q4 EPS of ($0.45), $0.07 better than the analyst estimate of ($0.52). Revenue for the quarter came in at $18.18 million versus the consensus estimate of $6.77 million.

For earnings history and earnings-related data on NGM Biopharmaceuticals, Inc. (NGM) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Smith-Midland Corporation (SMID) Tops Q2 EPS by 26c
• L3Harris CEO steps down amid conduct review, shares drop